Zhitong Finance App News, Kaituo Pharmaceutical-B (09939.HK) announced that its self-developed long-term safety clinical trial (“this long-term safety clinical trial”) for 1.0% treatment of androgen alopecia (“AGA” or “alopecia”) has been followed up with all subjects, showing good safety.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.